STOCK TITAN
  1. Home
  2. News
  3. BCTXW

BriaCell Therapeutics Corp - BCTXW STOCK NEWS

Welcome to our dedicated news page for BriaCell Therapeutics (Ticker: BCTXW), a resource for investors and traders seeking the latest updates and insights on BriaCell Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BriaCell Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BriaCell Therapeutics's position in the market.

News
BriaCell Partners with New York Cancer & Blood Specialists (NYCBS) for Pivotal Phase 3 Study of Bria-IMT™ in Advanced Breast Cancer
Rhea-AI Summary
BriaCell partners with NYCBS to evaluate Bria-IMT combination in Phase 3 study for advanced breast cancer patients in New York.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
partnership clinical trial
-
News
BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT™ in Advanced Metastatic Breast Cancer
Rhea-AI Summary
BriaCell's pivotal Phase 3 study of Bria-IMT™ in combination with an immune checkpoint inhibitor has been fully approved and will enroll patients with advanced metastatic breast cancer. Positive results could lead to full approval and marketing authorization for Bria-IMT™. The study's primary endpoint is overall survival. Bria-IMT™ is currently under Fast Track Designation by the FDA. Successful completion of the study would allow BriaCell to submit a Biologics License Application.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
clinical trial
-
News
BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer
Rhea-AI Summary
BriaCell reports strong patient survival benefit in advanced metastatic breast cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.14%
Tags
none
News
BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders
Rhea-AI Summary
BriaCell closes arrangement, spinning out pipeline assets to BriaPro Therapeutics Corp. BriaCell shareholders receive one common share of SpinCo for each BriaCell share held, and new common shares of BriaCell. BriaCell retains 66.6% of SpinCo common shares. BriaCell common shares to begin trading on September 5, 2023. Refer to proxy statement for more details.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
none
-
News
BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT™ in High-Risk Early-Stage Triple Negative Breast Cancer
Rhea-AI Summary
BriaCell announces plans for Phase 2 clinical study of Bria-IMT™ in combination with a check point inhibitor in TNBC patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
clinical trial
-
News
BriaCell Receives Court Approval for the Share Arrangement Spinning Out BriaPro Therapeutics (SpinCo) to Existing Shareholders
Rhea-AI Summary
BriaCell receives court approval for plan of arrangement to spin-out pipeline assets to BriaPro Therapeutics Corp.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
none
News
BriaCell Therapeutics Corp. Announces Voting Results From Special Meeting
Rhea-AI Summary
Shareholders approved spinout of BriaPro Therapeutics including pipeline assets for cancer treatment. Share reorganization expected by August 31, 2023. Closing subject to court and regulatory approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
none
-
News
BriaCell Awarded National Cancer Institute Grant to Advance its Bria-OTS™ Immunotherapy for Cancer
Rhea-AI Summary
BriaCell Therapeutics Corp. has been awarded a research grant by the National Cancer Institute (NCI) to advance its platform of personalized off-the-shelf immunotherapies for cancer. The non-dilutive grant will be used for the development of Bria-OTS™ for advanced metastatic breast cancer, prostate cancer, lung cancer, and melanoma. The company's approach has shown promising top-line survival and quality of life outcomes in patients. The NCI award validates their approach and may lead to future non-dilutive funding opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
none
-
News
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023
Rhea-AI Summary
IPA (IMMUNOPRECISE ANTIBODIES LTD.) reported a 6.7% increase in revenue for the fiscal year 2023, reaching $20.7 million. Adjusted for currency effects, the growth was 9.0%. The company also achieved its highest quarterly revenue total of $5.6 million. IPA's CEO, Dr. Jennifer Bath, expressed optimism for the future, highlighting the potential of their in silico suite of services and data management capabilities to drive growth in the coming year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
earnings
News
FDA Approves BriaCell’s Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.99%
Tags
fda approval
Stock BCTXW logo
BriaCell Therapeutics Corp

Nasdaq:BCTXW

BCTXW Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

BCTXW Stock Data

11.64M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
West Vancouver

About BCTXW

briacell therapeutics corp immunotherapy approaches to cancer management briacell is a los angeles headquartered biotechnology company focused on immunotherapy treatments for cancer management. to date, the company has been successful in developing its patented "briavax" vaccine and implementing two compelling fda phase-i studies with late-stage breast cancer patients, demonstrating unique and unprecedented results. briacell is focused on aggressively moving towards launching its next clinical trial, a phase-i/ii study, in order to apply its vaccine to a larger number of breast cancer patients and effectively progress its technology along the value chain. while the current corporate focus is breast cancer, the company has an eye towards potentially applying its vaccine technology to certain other cancer types as well.